Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptevo TherapeuticsAPVO +2.38%29 EV-to-OCF is 0.18 as of Aug. 11, 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Aptevo Therapeutics ranks worse than 73.76% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aptevo Therapeutics's Enterprise Value is $-4.95 Mil.
Aptevo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-26.98 Mil. Therefore, Aptevo Therapeutics's EV-to-OCF for today is 0.18.
The historical rank and industry rank for Aptevo Therapeutics's EV-to-OCF or its related term are showing as below:
APVO'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.18 Med: 0 Max: 0.19
Current: 0.18
During the past 13 years, the highest EV-to-OCF of Aptevo Therapeutics was 0.19. The lowest was 0.18. And the median was .
APVO's EV-to-OCF is ranked worse than 73.76% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs APVO: 0.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aptevo Therapeutics's PE Ratio (TTM) for today is calculated as:
Aptevo Therapeutics's share price for today is $4.136.
Aptevo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-203.661.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aptevo Therapeutics EV-to-OCF Related Terms
Aptevo Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Aptevo Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aptevo Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's EV-to-OCF falls into.
Aptevo Therapeutics's current Enterprise Value is $-4.95 Mil.
Aptevo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (APVO) has a EV-to-OCF of 0.18 as of Aug. 11, 2026. Over the past decade, Aptevo Therapeutics' EV-to-OCF has ranged from 0.18 to 0.19. According to the industry distribution chart, Aptevo Therapeutics ranks #1037 out of 1406 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Aptevo Therapeutics' EV-to-OCF too high?
Aptevo Therapeutics' current EV-to-OCF is 0.18. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.19. Based on the distribution chart, Aptevo Therapeutics ranks #1037 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' EV-to-OCF compare to SNGX and BCAB?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #1037 out of 1406 companies for EV-to-OCF. This places Aptevo Therapeutics in the lower half of its industry. Historically, Aptevo Therapeutics' own EV-to-OCF has ranged from 0.18 to 0.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Aptevo Therapeutics's current EV-to-OCF is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current EV-to-OCF of 0.18. The current EV-to-OCF is 0.18. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current EV-to-OCF is 0.18 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score
Get the complete analysis for APVO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APVO has been successfully added to your 
